Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium

Hürmeriç, Volkan; Vaddavalli, Pravin K.; Pérez, Víctor L.; Roman, Janika San; Yoo, Sonia H.

doi:10.2147/opth.s40400

Cited by 10 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For NRTs, two studies were of moderate risk in the bias due to confounding (D1) due to the lack of baseline information or appropriate analysis to control the confounding[ 25 , 26 ], two trials were of moderate risk in the bias due to missing data (D5) because they did not report the missing data[ 24 , 26 ], and two trials were of serious risk in the bias in the selection of the reported result (D7) because statistical analyses were not conducted in these trials[ 25 , 26 ]. All three NRTs were of low risk in the bias in the selection of participants into the study (D2), bias in the classification of interventions (D3), bias due to deviations from intended interventions (D4), and bias in the measurement of outcomes D6.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Lai,

Loh,

Chiou

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

Rehabilitation of lower limb amputation in developing countries is quite challenging. Though there are basic to highly advanced prostheses available in India, the set-up is still facing difficulties in developing countries. Prosthetic management is difficult due to lack of availability of prostheses and reduced affordability among low income populations. In this review we highlighted the lower limb amputation and prosthetic rehabilitation status in India. Currently, India is advancing well in the rehabilitation field, but further studies are required to provide more evidence and recommendation.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Lai,

Loh,

Chiou

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…The use of a nti-VEGF d rugs as a n adjuvant treatment following pterygium excision is controversial [ 20 21 22 23 24 25 26 27 ]. A subconjunctival injection of bevacizumab is reportedly effective in preventing the recurrence of pterygiums without causing any significant adverse effects [ 20 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…Although there are diverse treatment options available for the management of recurrent pterygium, the recurrence rate is as high as 55% [ 6 7 8 9 10 ]. Various adjunctive treatment methods, such as amniotic membrane transplantation and administration of an anti-vascular endothelial growth factor (anti-VEGF) drug or mitomycin C, have been used to reduce the recurrence rate after pterygium excision [ 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ]. However, the reported clinical outcomes of these treatment methods vary in study design, patient characteristics, geographic location, definition of recurrence, and follow-up period [ 11 ].…”

mentioning

confidence: 99%

Efficacy and Safety of a Large Conjunctival Autograft for Recurrent Pterygium

Lee

et al. 2017

Korean J Ophthalmol

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy and safety of pterygium excision using a large conjunctival autograft for the treatment of recurrent pterygium. Methods: The medical records of 120 patients (126 eyes) with recurrent pterygium were reviewed. For each affected eye, pterygium excision with a large conjunctival autograft was performed. The graft was harvested from the superior bulbar area and measured more than 8 × 10 mm in size. Only patients who completed at least six months of follow-up were included. Postoperative clinical outcomes, recurrence rate, and complications were analyzed. Patients with any evidence of recurrence after surgery received a subconjunctival bevacizumab injection. Results: The average patient age was 56.5 ± 10.2 years, and 45 out of 120 patients were male. The mean study follow-up period was 17.7 ± 17.6 months. Most patients were satisfied with the cosmetic outcome. Postoperative visual acuity improved from 0.69 to 0.75 (p < 0.05). Postoperative refractive astigmatism and corneal astigmatism decreased by 0.55 and 2.73 diopters, respectively (p < 0.05). The postoperative recurrence rate was 4.0%, and the average recurrence period was 7.4 ± 0.6 weeks. A subconjunctival injection of 5 mg bevacizumab was performed in cases of recurrence; no progression of the pterygium was observed following the injection. Postoperative complications included 2 cases of conjunctival graft edema in 2 eyes, 5 donor site scars in 5 eyes, 13 pyogenic granulomas in 13 eyes, and a conjunctival epithelial inclusion cyst in 7 eyes. Conclusions: Pterygium excision with a large conjunctival autograft for the treatment of recurrent pterygium produced an excellent cosmetic outcome, a low recurrence rate, and minimal complications. A subconjunctival bevacizumab injection given in cases of recurrence following surgery might be effective in preventing progression of the pterygium.

show abstract

“…The effect of anti-VEGF monoclonal antibody, like bevacizumab and ranibizumab, for preventing recurrence after pterygium surgery is controversial [19,26]. Conbercept exhibits potent anti-angiogenesis activity, and puissant anti-inflammation because of blocking all isoforms of VEGF-A, VEGF-B and PIGF, and a higher binding affinity than monoclonal antibody in vitro and in vivo [27].…”

Section: Tablementioning

confidence: 99%

Effect of multiple subconjunctival conbercept injections as an adjuvant to the surgical treatment of pterygium: a prospective randomised comparative 6-month follow-up study

Zhang

Tian

Zheng

et al. 2019

Eye

View full text Add to dashboard Cite

Objective To evaluate the safety and efficacy of multiple subconjunctival injections of conbercept for pterygium patients after surgery. Methods As a prospective randomised interventional trial, 96 eyes from 96 patients with a tendency to recur were collected and divided randomly into conbercept and 5-fluorouracil groups on the 5th day after pterygium. All patients received three subconjunctival injections of conbercept (0.2 ml) or 5-fluorouracil (0.2 ml) on the 5th day (baseline), and 2 and 4 weeks postoperatively. The pterygium morphology, colour intensity, recurrence, and complications were recorded and analysed pre-1st injection and 1 day, 1 week, 1 month, 3 months, and 6 months post-3rd injection. Moreover, no patient was drop-out. Results There were striking differences between the two groups on post-3rd injections 1 day, 1 week, 1 month, 3 months, and 6 months (p = 0.001, 0.002, 0.000, 0.000, and 0.002, respectively) with respect to colour intensity: the eyes in conbercept group were lighter than the 5-Fu group. On post-3rd injection 6 months, prominent disparities existed between the two groups with respect to pterygium morphology (p = 0.006) and recurrence (p = 0.002), occurred in the conbercept group prior to the 5-Fu group. Moreover, corneal abrasions were not noted in the conbercept group, which was significantly less than the 5-Fu group (17/48; p = 0.000). There was no conspicuous discrepancy between the two groups with respect to subconjunctival haemorrhage (p = 0.789) and persistent epithelial defects (p = 0.078). Conclusion Multiple subconjunctival conbercept injections as an adjunct therapy for pterygium surgery was shown to be safe, effective, and well-tolerated.

show abstract

Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium

Cited by 10 publications

References 24 publications

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Efficacy and Safety of a Large Conjunctival Autograft for Recurrent Pterygium

Effect of multiple subconjunctival conbercept injections as an adjuvant to the surgical treatment of pterygium: a prospective randomised comparative 6-month follow-up study

Contact Info

Product

Resources

About